Immutep (ASX:IMM) has unveiled a pair of significant clinical developments that underscore its ambition to reshape cancer treatment, announcing positive results in both soft tissue sarcoma and first-line non-small cell lung cancer at the 2025 European Society for Medical Oncology Congress in Berlin. …
Immutep unveils dual breakthroughs at ESMO 2025, strengthening case for Efti across multiple tumour types
October 20, 2025 Australian Biotech
Latest Video
New Stories
-
Vaccine confidence slips as Australians grow more concerned about access to healthcare
October 20, 2025 - - Latest News -
NZ's Pharmac proposes new rules to manage 'Options for Investment' list
October 20, 2025 - - Latest News -
Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies
October 20, 2025 - - Australian Biotech -
Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum
October 20, 2025 - - Australian Biotech -
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 - - Australian Biotech -
Biogen earns fourth 'Great Place to Work' sertification, strengthening culture of inclusion
October 20, 2025 - - Latest News -
Algorae Partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand
October 20, 2025 - - Latest News